Viking Cash Flows Other Operating from 2010 to 2025

VKTX Stock  USD 33.69  0.26  0.78%   
Viking Therapeutics Cash Flows Other Operating yearly trend continues to be fairly stable with very little volatility. Cash Flows Other Operating is likely to outpace its year average in 2025. During the period from 2010 to 2025, Viking Therapeutics Cash Flows Other Operating regression line of annual values had significance of  0.000088 and arithmetic mean of  2,714,757. View All Fundamentals
 
Cash Flows Other Operating  
First Reported
2015-03-31
Previous Quarter
-1.4 M
Current Value
-2 M
Quarterly Volatility
1.9 M
 
Yuan Drop
 
Covid
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 319 K, Interest Expense of 75.2 K or Selling General Administrative of 44.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.76. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Cash Flows Other Operating Growth Pattern

Below is the plot of the Cash Flows Other Operating of Viking Therapeutics over the last few years. It is Viking Therapeutics' Cash Flows Other Operating historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Flows Other Operating10 Years Trend
Slightly volatile
   Cash Flows Other Operating   
       Timeline  

Viking Cash Flows Other Operating Regression Statistics

Arithmetic Mean2,714,757
Coefficient Of Variation207.90
Mean Deviation4,920,459
Median1,717,687
Standard Deviation5,643,855
Sample Variance31.9T
Range16.3M
R-Value(0.82)
Mean Square Error11T
R-Squared0.68
Significance0.000088
Slope(976,216)
Total Sum of Squares477.8T

Viking Cash Flows Other Operating History

2025-2 M
2024-2.1 M
2022-2.3 M
2021448 K
20202.8 M
2019-7.1 M
2018-737 K

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Cash Flows Other Operating, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Flows Other Operating-2.1 M-2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.